← Oncology Approval Tracker

FDA DECISION ·

Ibrance + anti-HER2 therapy

palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy · Pfizer

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Maintenance for adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction therapy.

LAMPGEN ANALYSIS

Why it matters

PATINA tested CDK4/6 inhibition in maintenance after induction in a dual receptor-positive population. The maintenance setting and receptor combination define what the data can inform.

What research teams should watch

At the maintenance transition, confirm induction completion, absence of progression and both receptor results. Align hematology monitoring with HER2-directed and endocrine therapy.

PRIMARY RECORDS

Sources